Skip to main content

Table 2 BMI, percentage of body fat, and endocrine data of early treated (before 1st birthday; group A) and later treated (after 1st birthday; group B) patients at all observational time points are shown. aindicates a difference between the groups at the significance level of 0.05

From: Early start of growth hormone is associated with positive effects on auxology and metabolism in Prader-Willi-syndrome

Age

1 ± 0.25 yrs

2 ± 0.25 yrs

3 ± 0.5 yrs

4 ± 0.5 yrs

5 ± 0.5 yrs

Group

A (n = 21)

B (n = 32)

A (n = 21)

B (n = 41)

A (n = 21)

B (n = 41)

A (n = 20)

B (n = 41)

A (n = 11)

B (n = 39)

mean ± SD

 BMInonPWS-SDS

−1.73 ± 1.41

−0.99 ± 1.32

−1.04 ± 1.20

−0.88 ± 1.20

−0.16 ± 1.10

−0.62 ± 1.49

0.15 ± 1.16

0.02 ± 1.36

0.22 ± 0.92

0.18 ± 1.18

 BMIPWS-SDS

−0.49 ± 0.74

0.11 ± 0.77

−0.68 ± 0.69

−0.61 ± 0.71

−0.85 ± 0.77

−1.10 ± 0.86

−1.01 ± 0.81

−1.12 ± 0.95

−1.26 ± 0.64

−1.30 ± 0.82

 % body fat

    

14.74 ± 6.24

15.06 ± 5.54

17.52 ± 8.59

19.41 ± 6.57

19.42 ± 5.32

21.10 ± 4.80

 IGF-I SDS

−0.62 ± 1.62

−0.57 ± 1.69

−0.30 ± 2.02

0.32 ± 2.53

−0.86 ± 2.21

−0.57 ± 2.07

−0.74 ± 1.78

−0.47 ± 1.97

−0.35 ± 2.45

−0.98 ± 1.25

 IGFBP-3 SDS

0.25 ± 0.71a

−0.79 ± 0.69a

1.22 ± 0.76a

0.58 ± 0.96a

1.31 ± 0.78a

0.89 ± 0.91a

1.46 ± 1.03a

0.99 ± 0.81a

1.12 ± 1.19a

0.97 ± 0.91a